23 Jul, 2026
According to Straits Research, the global antibody specificity testing market size was valued at $1.00 billion in 2025 and is projected to reach $1.92 billion by 2034, growing at a CAGR of 7.52% during the forecast period 2026–2034.
The global antibody specificity testing market is witnessing significant growth, primarily driven by the rapid expansion of antibody-based therapeutics and biologics, including monoclonal antibodies, bispecific antibodies, biosimilars, and other complex formats. As pharmaceutical and biotechnology companies increasingly rely on antibody therapies for immunotherapy, targeted treatments, and companion diagnostics, there is a growing need to ensure the safety, efficacy, and reliability of these products. Antibody specificity testing plays a critical role in validating the binding accuracy of antibodies, minimizing off-target effects, preventing cross-reactivity, and ensuring that diagnostic and therapeutic applications perform as intended.
However, the adoption of antibody specificity testing faces certain challenges. The high cost and technical complexity associated with testing protocols pose significant barriers for smaller biotech companies, academic institutions, and organizations in emerging markets. Advanced testing requires multiple assay platforms, specialized analytical equipment, and highly trained personnel, which increases operational expenses and limits accessibility. On the other hand, the market presents promising opportunities in emerging regions such as the Asia Pacific, where growing biotechnology research, expanding pharmaceutical pipelines, and increasing investment in diagnostics and therapeutics are driving demand. As countries in these regions strengthen life science infrastructure and regulatory frameworks, antibody specificity testing services and kits are expected to see heightened adoption, creating substantial growth potential for manufacturers and service providers in the coming years.
sales@straitsresearch.com